Michael Brown MD Ph.D. and Judy Brown Research Consultants …
The News Review:
- Michael Brown MD Ph.D. and Judy Brown Research Consultants …
- Better health and prosperity in Europe via improved clinical research
- Aastrom Commends Expansion of Federal Support for Stem Cell Research
- Icagen Initiates Study of Senicapoc in Exercise Induced Asthma
- Contract working gains heft in clinical research sector
- Velos Inc. Appoints William Broucek Senior Director Professional …
Michael Brown MD Ph.D. and Judy Brown Research Consultants …
TMCnet
Brown previously served as Bioheart’s Chief Scientific fficer and Vice President of Clinical Affairs from 1999 to 2004 and as a consulting Senior Clinical Specialist from January 2005 to December 2006. Prior to that he was a clinical specialist at Medtronic Inc. Judy Brown was previously Director of Clinical Research at World Medical Manufacturing Corporation from May 1998 to August 2000 and served as a consultant for World Medical in 2001. Prior to this work she coordinated clinical trials at the Baptist Cardiac & Vascular Institute Miami from 1990 to 1997. Her prior experience was in basic science research at the University of Miami where the two met. They have 40 years of combined basic science and clinical research management experience between them.
Related from Insurancemonster: Brown & Brown Inc. Announces the Asset Acquisition of ne Source …
Better health and prosperity in Europe via improved clinical research
ScienceBlog.com
For Europe and for the rest of the world this effort will be of great importance for the quality of life of individuals and the wellbeing of society as a whole. To achieve this important objective the European Medical Research Councils (EMRC) at the ESF mandated the undertaking of a foresight study a so called Forward Look on ‘Investigator- Driven Clinical Trials’ (IDCT). “This project marks the most comprehensive examination and analysis of the issue in Europe and proposes particular steps towards better clinical research in Europe” said Dr. Carole Moquin-Pattey Head of EMRC and coordinator of the study. Investigator-driven clinical trials – trials instigated by academic researchers aimed at acquiring scientific knowledge and evidence to improve patient care – deal with potential diagnostic and therapeutic innovations that do not attract or could be even against commercial interest. Rarity is part of the problem: the more patients with a chance of survival the greater the likelihood that pharmaceutical companies will put money into clinical trials of new treatments. In the sorry economics of suffering and death osteosarcoma and fibrous dysplasia are known as orphan diseases partly because no wealthy pharmaceutical company wants to “adopt” them and partly because the incidence is so rare that there are too few patients in any one country for tests that will produce statistically reliable results.
Aastrom Commends Expansion of Federal Support for Stem Cell Research
MSNBC
While the Administration’s action this week primarily focuses on funding for embryonic stem cell research this level of interest also benefits research into therapeutic applications of stem cells from other sources” said George W. Dunbar President and CE of Aastrom. “Grant funding from the federal government is a vital source support required to sustain new clinical research. Medical breakthroughs in this sector have the potential of providing enormous benefit to patients. We look forward to reporting advancements in our clinical development efforts in the future. Story continues below ?advertisement |.
Icagen Initiates Study of Senicapoc in Exercise Induced Asthma
MSNBC
Consequently this study along with our ongoing study of allergic asthma will provide meaningful insight into the potential role of senicapoc in the management of this disease. The double-blind placebo-controlled parallel group study is designed to assess the safety and efficacy of senicapoc on pulmonary function in patients with exercise-induced asthma. Approximately 60 patients from 15 clinical research centers in the United States will be randomized (1:1) to receive senicapoc or placebo once a day for four weeks. The primary efficacy analysis is the comparison between treatment arms in the percent change in FEV1 the amount of air that can be forcefully exhaled in one second following exercise. FEV1 is a standard commonly used test to measure lung function. Results from this study are expected later this year. Story continues below ?advertisement |.
Contract working gains heft in clinical research sector
Pharma Times
The survey was conducted for clinical research network Redtree by Anderson Baillie in December 2008. From a sample base of some 6000 clinical research professionals working across international territories including North America the UK and Central and Eastern Europe 10% of the 365 survey respondents were currently operating as independent contractors but 60% had considered becoming contractors in the past. While the perceived benefits of contracting ? better remuneration independence and flexible working ? were offset in the survey by inhibitions about job security and loss of company benefits 55% of the respondents recognised there was an increasing shift towards contract-based employment in the sector with more than 20% seeing it as the prevailing dynamic. This dynamic ?seems to concur with the current cycle where large pharma organisations have shed staff in non-core areas to become more ?agile?? Redtree comments.
Velos Inc. Appoints William Broucek Senior Director Professional …
PR Newswire (press release)
Velos developed this role to address needs coming out of its significant growth during the past two years. Broucek was hired to ensure that superior customer service is sustained while its market leadership continues to expand. “Excellence in meeting the singular needs of each customer has to keep pace with the excellence and reputation of our clinical research software product suite” said John S. McIlwain President and CE of Velos. “Broucek is safeguarding that objective as he oversees and directs our front line project managers supporting them with strong technical expertise and resources. Broucek is a healthcare software professional with proven success leading professional services and operations groups to complete implementation projects of all sizes on time and within budget. Previously Broucek held senior positions in professional services and implementation management with Bay Area companies that include Agistix iKnowMed a Division of US ncology acis Healthcare Systems and Fritz Companies Inc.
Written by admin on March 12th, 2009 with
no comments.
Read more articles on News.